Isofol Medical: AGENT did not reach ORR and PFS endpoints with statistical significance - Redeye

Redeye is disappointed by Isofol’s phase III AGENT trial failing to meet its primary ORR and key secondary PFS endpoints with statistical significance. We judge this presents one of the worst possible outcomes, and any path forward is highly uncertain now. We lower our valuation accordingly.

Länk till analysen i sin helhet: https://www.redeye.se/research/849968/isofol-medical-agent-did-not-reach-orr-and-pfs-endpoints-with-statistical-significance?utm_source=finwire&utm_medium=RSS